FDA orphan drug designation: treatment of acute myeloid leukemia
All entries for: Nanjing RegeneCore Biotech Co.
January 5, 2026
Nanjing RegeneCore Biotech Co.
Orphan Drug Designation
Disease Area: Rare Diseases
FDA orphan drug designation: treatment of acute myeloid leukemia